The goal of this clinical trial is to learn about what doses of BTM-356 are safe to use in adults with advanced cancers in solid tumors. It will also learn about how effective different doses of BTM-3566 are in treating cancer. The main questions it aims to answer are:
What adverse events and toxicities (harmful side effects) are associated with different doses of BTM-3566? What are the blood levels of BTM-3566 in your body at different timepoints? What effect does BTM-3566 have on reducing tumor size and/or preventing the worsening of cancer? All participants will receive BTM-3566 and none will receive placebo (a look-alike substance that contains no drug).
Participants will:
* Take BTM-3566 for 7 days, then take a 7 day break. This 2 week dosing schedule of 7 days on/7 days off will continue until your disease worsens or you cannot tolerate treatment.
* Visit the clinic approximately 7 times during screening and the first month of treatment. Visits will be reduced to approximately 2 visits per month after.
* Keep a diary of when (and how much) BTM-3566 you take, along with how much you weigh on each dosing day.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Key Inclusion Criteria:
* Any advanced, unresectable and/or metastatic solid tumors except for primary brain cancer, breast cancer, prostate cancer, pancreatic cancer, pheochromocytoma, fibrolamellar carcinoma, adrenocortical carcinoma, or ocular or cutaneous melanoma.
* Must be refractory/relapsed after all standard therapies known to provide proven clinical benefit
* ECOG Performance Status 0 to 2
* Adequate organ function as defined by pre-specified laboratory values
* Life expectancy \> 3 months
* Women of child-bearing potential (or males with female partners of child-bearing potential) must agree to use adequate contraceptive measures throughout the study and for 90 days following last dose
Key Exclusion Criteria:
* Has not completed appropriate wash-out timeframes of prior anti-cancer treatments
* Has ongoing toxicities from prior anti-cancer treatments
* Has symptomatic or uncontrolled neurologic disease
* Has active and clinically significant bacterial, fungal or viral infection
* Cannot avoid use of moderate or strong CYP3A4 inhibitors or inducers; CYP2C19 substrates or OAT2 substrates with narrow therapeutic index; or drugs that prolong the QT interval throughout the study
* Has previously received a total anthracycline dose ≥ 360mg/m2 doxorubicin or equivalent
* Has a history of serious cardiac conditions or pulmonary or cerebrovascular events within 6 months of first dose
* Is pregnant or breastfeeding
Primary outcome measure(s)
Frequency and type of dose limiting toxicities — 28 days Frequency and type of dose limiting toxicities associated with each dose level of BTM-3566
Frequency and severity of adverse events — Through study completion, estimated 2 years Frequency and severity of adverse events according to NCI-CTCAE v 5.0
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.